Drug Trial Radar · NCT02711553
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
309
Actual
Start
May 19, 2016
Primary completion
Feb 16, 2018
Study completion Dec 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Mar 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
Conditions
- Biliary Tract Cancer
- Metastatic Cancer
- Advanced Cancer
Interventions
RamucirumabDrug
Administered IV
MerestinibDrug
Administered orally
CisplatinDrug
Administered IV
GemcitabineDrug
Administered IV
Placebo OralDrug
Administered orally
Placebo IVDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Randomization to Progressive Disease or Death from Any Cause (Up To 20 Months)
Locations
82 sites in 18 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
UCSF Medical Center at Mission Bay
San Francisco, California
Georgetown University Medical Center
Washington D.C., District of Columbia
University of Florida School of Medicine
Gainesville, Florida
Karmanos Cancer Institute
Detroit, Michigan
Washington University Medical School
City of Saint Peters, Missouri
Washington University Medical School
Creve Coeur, Missouri
Washington University Medical School
St Louis, Missouri
Washington University Medical School
St Louis, Missouri
Thomas Jefferson University
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Florida Cancer Specialists
Nashville, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
Fundacion Favaloro
Ciudad de Buenos Aires, Argentina
Fundación CORI para la Investigación y Prevención del Cáncer
La Rioja, Argentina
Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan
San Juan, Argentina
Alexander Fleming
CABA, BS, Argentina
Hospital de Gastroenterologia Udaondo
Capital Federal, Buenos Aires, Argentina
Fundacion Ars Medica
San Salvador de Jujuy, Jujuy Province, Argentina
Clinica Viedma
Viedma, Río Negro Province, Argentina
Centro Medico San Roque
San Miguel de Tucumán, Tucumán Province, Argentina
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Austin Health
Heidelberg, Victoria, Australia
Universitätsklinikum Salzburg
Salzburg, Austria
KH der Barmherzigen Brüder Wien
Vienna, Austria
Landesklinikum Wr. Neustadt
Wiener Neustadt, Lower Austria, Austria
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium
Cliniques universitaires Saint-Luc
Brussels, Brussels Capital, Belgium
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia
Fakultni Nemocnice v Motole
Prague, Czechia
Masarykuv onkologicky ustav
Brno, Brno-město, Czechia
Aarhus Universitetshospital, Aarhus Sygehus
Aarhus C, Denmark
Odense Universitetshospital
Odense C, Denmark
CHU de Besancon Hopital Jean Minjoz
Besançon, France
Hôpital C. HURIEZ
Lille, France
CHRU de Montpellier-Hopital St Eloi
Montpellier, France
Centre Antoine-Lacassagne
Nice, France
Gustave Roussy
Villejuif, France
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.